Leadartis reports its business strategy at BioSpain 2014

25-09-2014

Leadartis has participated in BioSpain 2014 recently held in Santiago de Compostela (November 24-26th). BioSpain was chosen to present our business to the sector since is the most important biotechnology event in Spain and one of the most important internationally.

Leadartis announces the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board

04-09-2014

Madrid (September 4th, 2014). Leadartis, a privately held biotechnology company, is pleased to announce the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board (SAB). Dr. Sanchez-Madrid together with the outstanding scientists and drug development professionals: Dr. L. Alvarez-Vallina, Dr. P. Kristensen, Dr. I. Melero and Dr. L.

Leadartis to present its business at BioSpain 2014 on September 24th, 2014

04-09-2014

Madrid (September 3rd). Leadartis, a privately held biotechnology company, is pleased to announce is participation at the BioSpain 2014 international biotechnology conference to be held in Santiago de Compostela (Spain) in September, 24th-26th, 2014

Leadartis reports an efficient method for production of Trimerbody® molecules in Pichia Pastoris

01-08-2014

In collaboration with prestigious academic institutions, LeadArtis´scientists demonstrated that single-chain fragment variable (scFv)-based N-terminal Trimerbody® molecules can be efficiently produced in the methylotrophic yeast Pichia pastoris (P. pastoris) in a trimeric fully functional active form. The yield of scFv-based N-terminal Trimerbody® molecules expressed in P. pastoris was about 20-fold higher than in mammalian cells. New marketed therapeutic proteins produced in Pichia evidence the rising interest of P.

LeadArtis announces financing and secures investors support.

01-02-2014

Current investors of LeadArtis and others have confirmed the release of additional funding to the company, which will enable acceleration of the development of the Trimerbody® protein engineering platform and drug candidates. The investor syndicate composed of three investment organizations with a strong biotech record continues to express strong confidence in LeadArtis platform and portfolio of new promising drug candidates.

LeadArtis announces the appointment of Dr. Juan J. Perez Villar as CEO.

01-02-2014

In his new position, Juan will be responsible for raising investment capital, providing strategic leadership and overseeing operations for the Company. Juan brings more than 18 years of experience in the sector having previously served as Business Development Partner at Biolty (Madrid, Spain), prior to that Juan was Director of the industrial affairs department at the CEU University (Valencia, Spain) and head of oncology group at Astellas/Agensys (Santa Monica, CA, USA) and Bristol Myers Squibb (Princeton, NJ, USA). Juan earned a M.S. in biochemistry and a Ph.D.

LeadArtis participates in the IACT Kick-off meeting

01-11-2013

The IACT Kick-off meeting took place November 12, 2013 in Frankfurt, Germany. Representatives of all partners, including all general assembly members and representatives of management team participated in the meeting.

LeadArtis will join and contribute to the IACT project of the 7th European Framework programme.

01-11-2013

European Framework programmes (FPs) are the European Union’s main instrument for funding European Medical Research. They support the creation of multidisciplinary networks designed to promote the collaboration of health-related industries and integrate European-wide research, “as well as build a ‘critical mass’ of expertise and excellence”.

LeadArtis reports the generation of monospecific and bispecific hexavalent trimerbody® molecules

05-11-2012

LeadArtis S.L. announced the generation of multivalent and multispecific trimerbodies. By fusing single-chain variable fragments(scFv) with the same or different specificity to both N- and C-terminus of the trimerizing scaffold domain, monospecific or bispecific hexavalent molecules were successfully produced and secreted as soluble proteins by transfected mammalian cells.

Syndicate content

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...